Document is current
Any future updates will be listed below
-
Authors
Sharpe, Lara
Sinclair, Justin
Kramer, Andrew
de Manincor, Michael
Sarris, Jerome
- License Information
-
More Information
Article History
Received: 22 April 2020
Accepted: 4 September 2020
First Online: 2 October 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: No funding was solicited or received for this manuscript. JS and JS conduct cannabis research as university members of the Australia Medicinal Cannabis Research and Education Collaboration (). J. Sarris has received consultancy payments from a cannabis manufacturing company as an independent scientific advisor (Australian Natural Therapeutics Group); this is however completely unrelated to this manuscript. He has also received either presentation honoraria, travel support, clinical trial grants, book royalties, or independent consultancy payments from: Integria Healthcare & MediHerb, Pfizer, Scius Health, Key Pharmaceuticals, Fiji Kava, Research Reviews, Taki Mai, Bioceuticals & Blackmores, Soho-Flordis, Healthworld, HealthEd, HealthMasters, Kantar Consulting, Elsevier, Chaminade University, International Society for Affective Disorders, Complementary Medicines Australia, SPRIM, Terry White Chemists, ANS, <i>Society for Medicinal Plant</i> and Natural Product Research, Sanofi-Aventis, Omega-3 Centre, the National Health and Medical Research Council, CR Roper Fellowship. J.Sinclair has sat on the Scientific Advisory Board for BioCeuticals. LS, AK, and MdM declare that they have no competing interests.
